Epizyme (NASDAQ:EPZM) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Epizyme (NASDAQ:EPZMGet Rating) in a research note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the company. Wedbush lowered Epizyme from an “outperform” rating to a “neutral” rating in a report on Monday, June 27th. Cowen lowered Epizyme from an “outperform” rating to a “market perform” rating and set a $1.50 price objective on the stock. in a report on Monday, June 27th. HC Wainwright dropped their price objective on Epizyme from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, June 3rd. Finally, Cowen lowered Epizyme from an “outperform” rating to a “market perform” rating and set a $1.50 price objective on the stock. in a report on Monday, June 27th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Epizyme currently has an average rating of “Hold” and a consensus price target of $3.00.

Epizyme Price Performance

NASDAQ:EPZM opened at $1.47 on Friday. The firm has a market capitalization of $247.44 million, a PE ratio of -0.85 and a beta of -0.41. The business’s fifty day moving average price is $1.48 and its 200 day moving average price is $1.12. Epizyme has a 12 month low of $0.41 and a 12 month high of $5.80.

Epizyme (NASDAQ:EPZMGet Rating) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.15. The firm had revenue of $27.53 million for the quarter, compared to analyst estimates of $10.11 million. Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 391.90%. As a group, equities analysts anticipate that Epizyme will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Epizyme

Hedge funds have recently made changes to their positions in the business. Kraematon Investment Advisors Inc. acquired a new stake in shares of Epizyme during the fourth quarter worth about $28,000. Bayesian Capital Management LP acquired a new stake in Epizyme in the fourth quarter valued at about $40,000. Strategic Blueprint LLC acquired a new stake in Epizyme in the second quarter valued at about $25,000. Verition Fund Management LLC acquired a new stake in Epizyme in the second quarter valued at about $34,000. Finally, Amalgamated Bank lifted its position in Epizyme by 65.1% in the first quarter. Amalgamated Bank now owns 26,516 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,458 shares during the period. Institutional investors and hedge funds own 76.45% of the company’s stock.

Epizyme Company Profile

(Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

Recommended Stories

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.